AAX Biotech AB, a Swedish start-up developing technologies for antibody therapeutics, has appointed Patrik Strömberg to its board. With over two decades’ experience in the scientific and business side of the pharmaceutical industry, Dr Strömberg is currently the CEO of AnaCardio. He previously held senior positions at AstraZeneca and Biovitrum/Sobi. Dr Strömberg holds a PhD in biochemistry from Karolinska Institutet and an MBA from Stockholm University, both in Sweden. AAX Biotech has developed platforms and enabling technologies to improve the performance and developability of antibody-based therapeutics.
AAX Biotech announced the appointment on 21 August 2024.
Copyright 2024 Evernow Publishing Ltd